Immunotherapy in Multiple Myeloma—Time for a Second Major Paradigm Shift
- 1 July 2021
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 17 (7) , 405-413
Abstract
Multiple myeloma (MM) is a genetically heterogenous disease and remains mostly incurable with a small group of patients achieving long-term disease remission. The past decade witnessed enormous efforts to break the circulus vitiosus of tumor-induced immunosuppression and to re-engage the immune system to fight cancer. The first-in-class anti-CD38 monoclonal antibody, daratumumab, has shown unprecedented responses especially in combination with other novel agents in both newly diagnosed and relapsed MM. There has been great interest in harnessing the power of T cells with bispecific antibodies and chimeric antigen receptor T-cell therapies in hematologic malignancies including MM. These immune-based approaches have shown notable antimyeloma effects with deeper, durable responses in early clinical trials of heavily pretreated patients with MM with limited therapeutic options. Several trials are underway investigating both single and combinatorial immune therapies at different stages with a hope to bring major transformation in MM. In the current review, we summarize how an immunologic approach offers promise for the treatment of MM and is setting the stage for second major paradigm shift 2 decades after the emergence of thalidomide and novel therapeutics.Keywords
This publication has 95 references indexed in Scilit:
- APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironmentBlood, 2016
- Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T CellsImmunity, 2016
- T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of ImmunotherapyCancer Immunology Research, 2016
- Elotuzumab Therapy for Relapsed or Refractory Multiple MyelomaNew England Journal of Medicine, 2015
- Targeting the bone marrow microenvironment in multiple myelomaImmunological Reviews, 2014
- Curing myeloma at last: defining criteria and providing the evidenceBlood, 2014
- Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T CellsClinical Cancer Research, 2014
- Vaccination with Dendritic Cell/Tumor Fusions following Autologous Stem Cell Transplant Induces Immunologic and Clinical Responses in Multiple Myeloma PatientsClinical Cancer Research, 2013
- Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysisBlood, 2011
- High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusionsBlood, 2001